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Open acca b s t r a c t
Tuberculosis (TB) is an uncommon cause of severe respiratory failure, even in highly endemic regions.
Mortality in cases requiring mechanical ventilation (MV) varies between 60 and 90%. The use of extra-
corporeal membrane oxygenation (ECMO) is not frequently needed in TB. We report the case of a 24 year
old woman diagnosed with bilateral pneumonia that required MV and intensive care, patient was
managed with prone ventilation for 48 h, but persisted in refractory hypoxemia. Etiological study was
only positive for mycobacterium tuberculosis. As a rescue therapy arterio-venous extracorporeal CO2
removal was started and lased for 4 days, but fails to support the patient due to greater impairment of
oxygenation. Veno-venous ECMO was then initiated, thus normalizes gas exchanged and allows lungs to
rest. ECMO was maintained for 36 days, with two episodes of serious complication treated successfully.
Given the absence of clinical improvement and the lack of nosocomial infection, at 42-day of ICU stay
methylprednisolone 250 mg daily for 4 days was started, since secondary organizing pneumonia asso-
ciated with TB was suspected. Thereafter progressive improvement in pulmonary mechanics and
reduction of pulmonary opacities was observed, allowing the ﬁnal withdrawal of ECMO. Percutaneous
tracheostomy was performed and the patient remained connected until her transfer to her base hospital
at day 59 of admission to our unit. The tracheostomy was removed prior to hospital discharge, and the
patient is today at home. Prolonged ECMO support is a useful and potentially successful tool in cata-
strophic respiratory failure caused by TB.
 2013 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Hypoxic acute respiratory failure (ARF) and acute respiratory
distress syndrome (ARDS) are rare complications of pulmonary
tuberculosis (TB) that can often be fatal, particularly in patients
with extensive TB related lung damage. The reported mortality rate
of TB associated with ARF requiring mechanical ventilation (MV)
varies from 60 to 80% [1]. Factors independently associated with
mortality in TB pneumonia are advanced age, the presence of shock
unrelated to sepsis, poor nutritional status and delay in the estab-
lishment of diagnosis and institution of speciﬁc therapy [2].
Lung protective mechanical ventilatory support is the current
standard of care for patients with ARF while veno-venous extra-
corporeal membrane oxygenation (VV-ECMO) is an accepted
alternative option in refractory hypoxemic respiratory failure. VV-
ECMO ensures adequate oxygenation and CO2 removal avoidinggmail.com (T. Regueira).
ess under CC BY-NC-ND license.ventilator induced lung injury. The decision to continue prolonged
VV-ECMO support can be difﬁcult and challenging as limited data
are available. In particular, the healing rate of TB pulmonary lesions
is characteristically slow and, thus, the need for prolonged venti-
latory and non-ventilatory support modalities can be expected in
cases of ARF secondary to TB. There are few reports of VV-ECMO for
ARF due to TB [2e6], probably because the low frequency of this
complication, but also due to cost and accessibility issues.
We describe the case of a young woman with refractory respi-
ratory failure caused by pulmonary TB, which was unresponsive to
conventional MV but was successfully managed with prolonged
VV-ECMO support. To our knowledge, this is the second published
case describing long-term EMCO in TB related ARF [5e7].
2. Clinical case
A 24-year old woman with a background of recently diagnosed
laryngeal papilloma and active smoking, who had been previously
treated at another hospital, was admitted to our unit with a rapidly
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described a history of two months of fever, weight loss of 5 kg,
cough and non-hemoptoic sputum.
Broad-spectrum intravenous antibiotics (Imipenem and Van-
comycin) were started. Anti-TB treatment (Isoniazid 300 mg,
Rifampicin 600 mg, Pyrazinamide 1500 mg and Ethambutol
1200 mg) was added shortly after when acid-fast bacilli where
identiﬁed through sputum microscopy. Her respiratory condition
worsened leading to intubation and MV within hours of admission.
Sedation, paralysis and lung protective ventilation (tidal volume
6 mL/kg ideal body weight) were provided. The PO2:FiO2 ratio
remained below 90 while the oxygenation index was at 22. A chest
radiograph showed diffuse bilateral alveolar opacities and right
pleural effusion. Arterial blood gases showed a pCO2 of 72.4mmHg,
a pH 7.26 and bicarbonate of 32 mEq/L. Lactate was 2.2 mmol/L and
noradrenaline (0.05e0.1 mg1kg1min) was required to maintain a
mean arterial pressure above 65 mmHg. The patient remained
afebrile, C-reactive protein (CRP) was 22.3 mg/dl, and blood and
urine cultures were negative. Her APACHE II and SOFA scores were
22 and 12, respectively .Legionella pneumophila urinary antigens,
mycoplasma and Chlamydia pneumonia serology were all negative.
Inmmunological screening was negative, with a complement C3 of
73 mg/dl and C4 of 17 mg/dl, the CD4 count was 252 and the CD8
was 97cells/mm [3]. Serum cortisol, measured at two different in-
tervals, was below detection limits and computed tomography (CT)
scan of the abdomen was normal. At this point, adrenal insufﬁ-
ciency secondary to TB was diagnosed and an intravenous hydro-
cortisone 100 mg t.i.d. was started.
During the ﬁrst four days in our ICU, the patient progressed with
worsening respiratory failure despite receiving lung protective MV
with recruitment maneuvers and high levels of PEEP, according the
"Lung Open Ventilation" protocol [8]. A trial of prone position venti-
lation, lasting a total of 48 h, was started on day 1 with no effect and
persistence of refractory hypoxemia, secondary hypercapnic acidosis,
airway plateau pressures >35 cmH2O, and poor lung compliance.
On day 4, the patient developed a right pneumothorax, with
complete lung re-expansion after the insertion of a pleural tube. AFig. 1. Patient’s clsmall amount of pleural ﬂuid was drained, which had the charac-
teristics of an empyema. Tidal volumes were reduced to 4 mL/kg
due to progressively higher airway pressures, and an arterio-
venous carbon dioxide removal system (Novalung), via cannula-
tion of the femoral artery and vein, was used to control PaCO2 and
pH [9]. This system allowed adequate control of hypercapnia and
permitted an increase of PEEP, with a moderate improvement in
oxygenation. However, after four days of arterio-venous carbon
dioxide removal, oxygenation worsened and a VV-ECMO was
started on the ninth day after admission. Bilateral femoral drainage
cannulas (21 and 15 F) and a return cannula (19 F) in the right ju-
gular vein were inserted percutaneously and connected to a 1.8
M2Quadrox D oxygenator (Maquet) with blood ﬂows between 3.5
and 5 l/min and 100% oxygen was provided at 6e8 l/min. Anti-
coagulationwith unfractioned heparin infusionwas started, aiming
for an activated coagulation time between 180 and 200 s. Adequate
gas exchange was achieved after initiation of VV-ECMO and the MV
settings were adjusted to provide low tidal volumes and respiratory
frequency (Fig. 1).
During the ﬁrst two weeks of VV-ECMO, CRP and others in-
ﬂammatory parameters decreased and the lungs were ventilated
with very low tidal volumes (Vt 130 ml, RR 10, PEEP 10, FiO2 0.4).
However, poor oxygenation, elevated airway pressures and signif-
icant hypercapnic acidosis were observed during trials of VV-ECMO
weaning. Throughout this period, two thoracic CT scans showed no
signiﬁcant improvement of the lung inﬁltrates (Fig. 2). Moreover,
no clots were observed in the VV-ECMO circuit during this time.
On the 20th day, a life-threatening hemorrhagic complication
occurred when the lectern supporting the oxygenator fell down
and broke. The nurse in charge promptly clamped the cannulas and
the oxygenator was replaced within the next 15 min. The patient,
whom remained stable throughout the event, required a trans-
fusion of 3 units of packed red blood cells. Later on, the patient
presented one more episode of right pneumothorax which was
successfully treated by pleural chest tubes (Fig. 1).
On the 28th day of VV-ECMO, a bronchoalveolar lavage was
performed to rule out active infection prior to use high doseinical course.
Fig. 2. Computed tomography scan progress.
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negative and microscopy did not show acid-fast bacilli. Methyl-
prednisolone was started at 250 mg/day for 4 days.
On the following days, an improvement in pulmonary compli-
ance and gas exchange was progressively observed, with gradual
resolution of lung inﬁltrates on chest radiograph. On the 36th day
of VV-ECMO, lung compliance and gas exchange were good enough
to resume conventional MV. ECMO was weaned and removed.
After decannulation, anticoagulation was stopped and a percu-
taneous tracheostomy was then performed. The patient was
weaned off the ventilator with a gradual decrease in pressure
support and intensive muscular and nutritional rehabilitation. On
the 59th day since her admission to the unit, the patient was
transferred back to her original hospital, from which she was dis-
charged to her home 20 days later.
After nine months of being discharged from the hospital, she is
at your home performing basic activities, both physically as
cognitive nearly normal. Their only limitation is given bypersistence yet of using a tracheostomy with speaking valve due to
subglottic stenosis. Also the diagnosis of laryngeal papilloma was
rejected, since it was shown to correspond to TB.
3. Discussion
TB is an increasing global health issue, affecting a third of the
world’s population and causing signiﬁcant morbidity and death. On
rare occasions, TB can lead to ARDS. In one study of 187 patients
admitted to an intensive care unit with ARDS, TB was found to be
the cause in nine patients (4.9%) [1]. Over a 10-year period in the
province of Manitoba in Canada, only 13 patients with TB requiring
MV were identiﬁed, eight of which developed ARDS [10]. In-
hospital mortality rate in 41 patients with ARDS caused by TB
was 65.9%, a rate signiﬁcantly higher than that in patients with
ARDS caused by other diseases [11]. One possible explanation for
the observed elevated mortality, besides the aggressive course of
the disease, is the failure to recognize TB as a cause of severe
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treatment [11].
Conventional treatment of ARF includes protective MV by
limiting tidal volume [12] and lung recruitment maneuvers [8],
pursuing negative ﬂuid balance [13] and adequately treating the
cause. VV-ECMO is an alternative for management of catastrophic
respiratory failure, which is indicated after high PEEP low Vt
ventilation, prone positioning and paralysis have failed to control
hypoxemia or hypercapnia.
Homan et al. reported the ﬁrst case of ECMO associated with TB
in 1975, but the patient died after only ﬁve days on ECMO [5].
However, the diagnosis of TB was done at autopsy and therefore no
anti-TB drug treatment had been administered. From 1987 to 2012,
several studies of TB-related ARF requiring VM, do not report
extracorporeal pulmonary support [1,2,10,11,14,15].
In pediatric patients, two cases have been reported. The ﬁrst
case is of a fourteen-year old female patient with miliary TB who
received extracorporeal CO2 removed for 6 days, which survived an
had a good pulmonary and cognitive functions evaluated at 18
months [16]. The second case was a 15-year old patient with TB
pneumonia, which was successfully treated with VV-ECMO for a
period of 6 days [6].
The longest reported period of extracorporeal support corre-
sponds to a 20 year old femalewith TB pneumonia treatedwith VV-
ECMO for 89 days [7]. A normal functional status was reported at 6
months of follow-up. In this case, as in ours, early anti-tuberculosis
drug treatment in ICU and protective MV may have helped in res-
olution of the disease.
Complications of VV-ECMO can either bemechanical ormedical.
We use heparin-coated circuits and systemic anticoagulation to
minimize the risk of clots, which can cause oxygenator failure,
consumption coagulopathy, and pulmonary embolism. However, a
life-threatening hemorrhagic complication occurred when the
lecternwhere the oxygenator had been placed, fell down and broke.
Fortunately, our staff resolved promptly this complication,
emphasizing the importance of performing this procedure at
technically trained centers.
Upon follow-up, our patient did not present any other major
ECMO-related complications, such as neurologic deﬁcit, metabolic
derangements, myocardial stunning, arrhythmias, or other organ
failures.
Intravenous methylprednisolone (total dose of 1 g) was started
on day 37 and its use was temporarily associated with the pro-
gressive and steady improvement of the patient’s respiratory
function. If this therapy allowed us to wean off VV-ECMO two
weeks later is debatable, as published data on the use of steroids in
TB is scant and of poor quality. A retrospective study in patients
with ARF secondary tomiliary or TB pneumonia requiringMV could
not identify a positive effect of steroids on mortality, days on MV or
oxygenation [14].
The scarce literature regarding pulmonary TB related ARF, and
pulmonary function andmechanics in these patients is noteworthy.
This report suggests that VV-ECMO can be used as an alternativetherapy for refractory hypoxemia secondary to pulmonary TB. This
is a potentially reversible condition, and the use of VV-ECMO plus
anti-TB treatment was life-saving in this patient, while sparing the
harmful effects of conventional mechanical ventilation.
ADC: accidental disconnection circuit ECMO; BAL: Bron-
choalveolar lavage; EC: ECMO circuit exchange; CT: computed to-
mography scan; MTP: methylprednisolone; MV: mechanical
ventilation PNX: pneumothorax; TB: Mycobacterium tuberculosis;
TR: tracheostomy; TH-PNX: Tension hemo-pneumothorax.References
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